Silent venous thromboembolism before treatment in endometrial cancer and the risk factors

T Satoh*,1, K Matsumoto1, K Uno2, M Sakurai1, S Okada1, M Onuki1, T Minaguchi1, YO Tanaka3, S Homma2, A Oki1 and H Yoshikawa1

1Department of Obstetrics and Gynecology, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan; 2Cardiovascular Division, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan; 3Department of Radiology, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan

Venous thromboembolism (VTE) often occurs after surgery and can even occur before surgery in patients with gynaecological malignancies. We investigated the incidence of VTE before treatment of endometrial cancer and associated risk factors. Plasma D-dimer (DD) levels before initial treatment were examined in 171 consecutive patients with endometrial cancer. Venous ultrasound imaging (VUI) of the lower extremities was performed in patients with DD ≥ 1.5 μg ml⁻¹, as the negative predictive value of DD for VTE is extremely high. For patients with deep vein thrombosis (DVT), pulmonary scintigraphy was performed to ascertain the presence of pulmonary thromboembolism (PTE). Risk factors for VTE were analysed using univariate and multivariate analyses for 171 patients. Of these, 37 patients (21.6%) showed DD ≥ 1.5 μg ml⁻¹, 17 (9.9%) displayed DVT by VUI and 8 (4.7%) showed PTE on pulmonary scintigraphy. All patients with VTE were asymptomatic. Univariate analysis for various risk factors revealed older age, non-endometrioid histology and several variables of advanced disease as significantly associated with VTE before treatment. Obesity, smoking and diabetes mellitus were not risk factors. Multivariate analysis confirmed extratumoral spread and non-endometrioid histology as independently and significantly associated with risk of VTE. These data suggest that silent or subclinical VTE occurs before treatment in at least around 10% of patients with endometrial cancer. Risk factors for VTE before treatment might not be identical to those after starting treatment.

British Journal of Cancer (2008) 99, 1034–1039. doi:10.1038/sj.bjc.6604658 www.bjcancer.com
Published online 9 September 2008 © 2008 Cancer Research UK

Keywords: endometrial adenocarcinoma; deep vein thrombosis; pulmonary thromboembolism; plasma D-dimer

Deep vein thrombosis (DVT) and subsequent pulmonary thromboembolism (PTE) represent potentially lethal perioperative complications associated with major pelvic or abdominal operations (Turpie et al, 2002). Deep vein thrombosis is known to occur in the postoperative period or during the course of postoperative therapy in 9.8–57.1% of patients with endometrial carcinoma (Clarke-Pearson et al, 1983; Crandon and Koutts, 1983; Gore et al, 1984; von Tempelhoff et al, 2000). Several guidelines (Greets et al, 2001; Nicolaides et al, 2001, Committee on Practice Bulletins – Gynecology, American College of Obstetricians and Gynecologists, 2002) have focused on intra- and postoperative management for preventing venous thromboembolism (VTE). For the prevention of postoperative DVT, we usually use elastic stockings during surgery and intermittent pneumatic compression during and after surgery. However, if DVT exists before the treatment of endometrial carcinoma, such preventative measures may be ineffective or possibly dangerous for lethal PTE.

D-dimer (DD) is a degradation product of fibrin and reflects fibrin concentration. Although increased plasma DD level is generally thought to be associated with the presence of DVT, the positive predictive value of DD is 36–44%. Conversely, the negative predictive value of DD is 89–100% (Bounaumeaux et al, 1991; Harrison et al, 1993; Wells et al, 2003; Righini et al, 2006). We have recently reported that increased DD levels are associated with the presence of silent VTE before treatment in ovarian cancer (DD < 1.5 μg ml⁻¹, 0 of 26 (0%); DD ≥ 1.5 μg ml⁻¹, 18 of 46 (39%)) (Satoh et al, 2007). A suitable cutoff value for detecting VTE in patients with ovarian cancer seems to be 1.5 μg ml⁻¹, which offers 100% sensitivity and 100% negative predictive value, despite low specificity (47.2%) and low positive predictive value (38.3%). This study therefore aimed to clarify the incidence of VTE before treatment in endometrial cancer patients with DD ≥ 1.5 μg ml⁻¹ and associated risk factors.

MATERIALS AND METHODS

Patients

Between January 2004 and December 2007, a total of 171 consecutive patients with histologically confirmed endometrial carcinoma were enrolled in this study. Two patients who underwent emergent hysterectomy for vaginal bleeding were not included. Five patients for whom histological diagnosis was changed from endometrioid carcinoma to carcinosarcoma after surgery were likewise excluded from the study. All study protocols were approved by the institutional review board at University of Tsukuba Hospital, and all patients provided written informed consent.
Management of patients with VTE before treatment

Anticoagulant therapy was started using unfractionated heparin immediately after diagnosis of VTE. Therapy was continued until initial treatment, comprising surgery or chemotherapy, for all patients with VTE. We always administered anticoagulant therapy after surgery in these patients. In addition, one of the following managements was selected in some patients: placement of an inferior vena cava filter (IVCF) before upfront surgery; or neoadjuvant chemotherapy (NAC) followed by surgery.

Inferior vena cava filter placement was used before upfront surgery to prevent lethal PTE in patients with DVT in proximal veins, such as iliac and femoral veins or floating DVT in peripheral veins. Neoadjuvant chemotherapy followed by surgery was selected for patients with apparent stage III/IV endometrial cancer and chemosensitive tumour histology, such as serous or endometrioid type as estimated on biopsy and excessively increased CA125 level. We administered a paclitaxel and carboplatin (TC) regimen comprising paclitaxel (175 mg m⁻² infused over >3h) and AUC 6 of carboplatin.

We also used pelvic irradiation, chemotherapy using a TC regimen or sequential chemoradiation therapy (TC regimen followed by pelvic and/or paraaortic radiation) as postoperative therapy for high-risk patients with stage Ic-IV endometrial cancer.

For patients with lower DD levels (<1.5 µg ml⁻¹) and patients with higher DD levels (≥1.5 µg ml⁻¹) but without VTE, compression stockings and intermittent pneumatic compression were used during and after surgery to prevent postoperative VTE. Low-molecular-weight heparin was also administered before and after surgery in patients with BMI ≥28 kg/m² and patients who had been administered anticoagulative medication due to a past history of cerebral infarction or atrial fibrillation.

RESULTS

Plasma level of DD and incidence of VTE before treatment

Plasma DD level was above the reference value (0.5 µg ml⁻¹) in 74 of 171 patients with endometrial cancer (43.3%). Thirty-seven (21.6%) patients showed DD ≥1.5 µg ml⁻¹. Subsequent VUI and PS revealed DVT in 17 patients (9.9%) and PTE in 8 patients (4.7%) (DVT alone, n = 9; DVT plus PTE, n = 8) before initial treatment. The most proximal location of DVT in these patients was the peroneal vein in eight patients, popliteal vein in two patients and soleal vein in seven patients. Mean DD level in 17 patients with VTE was 7.75 µg ml⁻¹ (range, 1.7–21.6). D-dimer levels were associated with the incidence of VTE (1.5–2.9 µg ml⁻¹, 3 out of 16 (13.6%); 3.0–4.5 µg ml⁻¹, 3 out of 6 (50.0%); and >4.5 µg ml⁻¹, 11 out of 15 (73.3%); P-value for trend = 0.009). All patients with VTE were asymptomatic when VTE was identified.

As VUI was performed only in patients with DD ≥1.5 µg ml⁻¹, sensitivity, specificity and negative predictive values were not able to be evaluated. The positive predictive value of DD using 1.5 µg ml⁻¹ as the cutoff level for silent VTE was 46.0% (17/37).

Risk factors for VTE before treatment

Table 1 shows relative risks for VTE according to personal characteristics, direct invasion, tumour extension, histology and tumour markers. Study variables determined before initial treatment were used in this analysis, with tumour extension (presumed stage) and myometrial invasion from imaging studies, histology from endometrial biopsy and tumour markers before treatment. Among these variables, older age, large tumour size in the uterine cavity, deep myometrial invasion, extrauterine spread, massive ascites, ovarian metastasis, paraaortic lymph node swelling, peritoneal dissemination, non-endometrioid histology, clear cell histology and increased tumour markers (CA125, CA19-9

© 2008 Cancer Research UK

British Journal of Cancer (2008) 99(7), 1034–1039
Table 1  Relative risks (ORs) of venous thromboembolism according to personal characteristics, tumour extension, direct invasion, histology and tumour markers

| Characteristics                                              | Incidence rate | OR (95% CI) | P-value |
|--------------------------------------------------------------|----------------|-------------|---------|
| **Age (years)**                                              |                |             |         |
| < 60                                                         | 6/103 (5.8%)   | Reference   |         |
| ≥ 60                                                         | 11/68 (16.2%)  | 3.12 (1.09 – 8.89) | 0.03 |
| **Body mass index (kg/m²)**                                  |                |             |         |
| < 25                                                         | 12/103 (11.7%) | Reference   |         |
| ≥ 25                                                         | 5/68 (7.4%)    | 0.61 (0.20 – 1.79) | 0.88 |
| **Smoking**                                                  |                |             |         |
| Non-smoker                                                   | 15/158 (36.8%) | Reference   |         |
| Smoker                                                       | 2/13 (100%)    | 1.77 (0.35 – 8.57) | 0.49 |
| **Menopause**                                                |                |             |         |
| No                                                           | 4/38 (10.5%)   | Reference   |         |
| Yes                                                          | 13/133 (9.7%)  | 0.92 (0.28 – 3.01) | 0.52 |
| **Parity**                                                   |                |             |         |
| < 3                                                          | 11/131 (8.4%)  | Reference   |         |
| ≥ 3                                                          | 6/40 (15.0%)   | 1.93 (0.66 – 5.59) | 0.18 |
| **Diabetes mellitus**                                        |                |             |         |
| No                                                           | 13/144 (9.0%)  | Reference   |         |
| Yes                                                          | 4/27 (100%)    | 1.75 (0.53 – 5.85) | 0.27 |
| **Anticoagulative medication for brain or heart disease**    |                |             |         |
| No                                                           | 17/166 (10.2%) | Reference   |         |
| Yes                                                          | 0/5 (0.0%)     | 0           | 1.00   |
| **Tumour size in uterine cavity (MRI) (mm)**                 |                |             |         |
| < 60                                                         | 6/134 (4.5%)   | Reference   |         |
| ≥ 60                                                         | 11/26 (29.7%)  | 9.03 (3.06 – 26.6) | <0.0001 |
| **Myometrial invasion (MRI)**                                |                |             |         |
| ≤ 1/2                                                        | 7/120 (5.8%)   | Reference   |         |
| > 1/2                                                        | 10/51 (19.6%)  | 3.94 (1.41 – 11.0) | 0.009 |
| **Tumour extension (CT/MRI)**                                |                |             |         |
| Localised to the uterus                                      | 3/120 (2.5%)   | Reference   |         |
| Extrauterine spread                                          | 14/51 (27.5%)  | 14.8 (4.02 – 54.2) | <0.0001 |
| **Pleural LN swelling > 10 mm (CT)**                        |                |             |         |
| Absent                                                       | 11/141 (7.8%)  | Reference   |         |
| Present                                                      | 6/30 (20.0%)   | 2.95 (0.997 – 8.75) | 0.053 |
| **Paraaortic LN swelling > 10 mm (CT)**                      |                |             |         |
| Absent                                                       | 10/150 (6.7%)  | Reference   |         |
| Present                                                      | 7/21 (33.3%)   | 7.00 (2.30 – 21.3) | 0.001 |
| **Massive ascites (CT)**                                    |                |             |         |
| Absent                                                       | 14/165 (8.48%) | Reference   |         |
| Present                                                      | 3/6 (50%)      | 10.8 (1.99 – 58.5) | 0.01  |
| **Ovarian metastasis (MRI)**                                 |                |             |         |
| Absent                                                       | 12/158 (7.6%)  | Reference   |         |
| Present                                                      | 5/13 (38.5%)   | 7.60 (2.15 – 26.9) | 0.004 |
| **Peritoneal dissemination (CT)**                            |                |             |         |
| Absent                                                       | 10/154 (6.5%)  | Reference   |         |
| Present                                                      | 7/17 (53.9%)   | 10.1 (3.16 – 32.1) | 0.0003 |
| **Distant metastasis except for peritoneal dissemination (CT or physical examination)** | 15/166 (9.0%) | Reference |         |
| **Histology**                                                |                |             |         |
| Endometrioid carcinoma                                       | 9/150 (6.0%)   | Reference   |         |
| Non-endometrioid carcinoma                                   | 8/21 (38.1%)   | 9.64 (4.46 – 46.0) | 0.0002 |
| Serous carcinoma                                             | 3/9 (33.3%)    | 7.83 (1.68 – 36.6) | 0.02  |
| Clear cell carcinoma                                         | 4/6 (66.7%)    | 31.3 (5.05 – 195) | 0.0004 |
and CEA) were significantly associated with VTE before treatment in univariate analysis. Subsequently, we performed the multivariate analysis using several significant variables in the univariate analysis. In the multivariate analysis, we focused on the following four representative variables, because there were apparent correlations among some variables (data not shown). ‘Tumour extent (extrauterine spread)’ was selected out of various significant variables representing tumour extension or metastasis including tumour markers. Similarly, we selected ‘myometrial invasion’ over ‘tumour size in the uterine cavity’ as a factor representing direct invasion and ‘non-endometrioid histology’ over ‘clear cell histology’ as a factor representing histology. Multivariate analysis for age, extrauterine spread, myometrial invasion and non-endometrioid histology confirmed extrauterine spread and non-endometrioid histology as independently and significantly associated with the risk of VTE before treatment (Table 2).

Management of VTE before treatment

Anticoagulant therapy using unfractionated heparin was administered before initial treatment for all 17 patients with VTE and after surgery for 14 patients who underwent primary or interval surgery. Three patients underwent no surgery because two patients displayed disease progression during NAC and the remaining one patient had severe heart disease. In addition to anticoagulant therapy, the placement of IVCF before upfront surgery was used for one patient with floating DVT, and NAC was performed for five patients. In summary, we managed patients with VTE before treatment as follows: (1) anticoagulant therapy alone in 11 patients; (2) upfront surgery with placement of IVCF in 1 patient; and (3) NAC followed by surgery in 5 patients.

VTE after commencement of treatment

None of the 17 patients with silent VTE before treatment developed clinical manifestations of VTE after the commencement of treatment, whereas 7 of the remaining 154 patients (4.6%) developed VTE (DVT alone, n = 4; DVT plus PTE, n = 3), after surgery in 3 patients and during chemotherapy in 4 patients. Of these seven patients, four patients had asymptomatic VTE (DVT alone, n = 3; DVT plus PTE, n = 1), and VTE was identified on routine CT and subsequent PS after surgery or during chemotherapy. Three of the seven patients showed DD >1.5 μg ml⁻¹ before treatment, although DVT was not detected by VUI.

DISCUSSION

This study detected silent DVT and DVT plus PTE before treatment in 9.9 and 4.7%, respectively, of patients with endometrial cancer. These incidences appear lower than 25.0 and 11.1%, respectively, in ovarian cancer reported in our previous paper (Satoh et al, 2007), although incidences in endometrial cancer were higher than the 5.2 and 1.2% in cervical cancer, respectively (unpublished data). As for DD level, 21.6% showed levels >1.5 μg ml⁻¹ in endometrial cancer, suggesting a lower percentage than the 63.9% in ovarian cancer and higher than the 14.5% in cervical cancer (unpublished data). However, several studies have documented higher incidence of postoperative DVT and PTE in endometrial cancer than in ovarian cancer (Clarke-Pearson et al, 1983; Crandon and Koutts, 1983; Gore et al, 1984; Suzuki et al, 2005). Incidence of silent VTE before surgery is unlikely to account for the high incidence of VTE after surgery in endometrial cancer.

Univariate and multivariate analyses revealed extrauterine spread and non-endometrioid histology as independently and significantly associated with the risk of VTE before treatment in endometrial cancer. Many variables regarding advanced disease were identified as significant risk factors for VTE before treatment.
in endometrial cancer, whereas our recent study revealed that various risk factors regarding advanced disease other than massive ascites were not significant risk factors for VTE before treatment in ovarian cancer. As for VTE after surgery or during treatment, a considerable number of previous reports have indicated advanced disease as a significant risk factor for VTE in gynaecological malignancies (Dubuc-Lissoir et al, 1999; Agnelli et al, 2006; Wang et al, 2006).

Among non-endometrioid histologies, clear cell histology seems to represent the highest risk factor (clear cell histology, 4 out of 6 (66.7%); non-clear cell histology, 4 out of 15 (26.7%)). We have recently reported clear cell histology as a strong risk factor for VTE before treatment in ovarian cancer (Satoh et al, 2007), and clear cell carcinoma shows significantly stronger expression of tissue factor, a major factor in the procoagulant activities of cancer cells, as compared with non-clear cell carcinoma (Uno et al, 2007).

Several published reports support the association between clear cell histology and VTE in ovarian cancer (Goff et al, 1996; Recio et al, 1996). These reports have postulated that patients with clear cell histology display a significantly higher incidence (11 – 42%) of VTE as compared with those with non-clear cell histology in the immediate postoperative period and during primary chemotherapy. Goff et al (1996) reported two ovarian cancer patients with clear cell histology displaying DVT as a presenting symptom before surgery. We have also reported an endometrial cancer patient with clear cell histology showing VTE before treatment (Toyoda et al, 2005). The same histology among different organs of mullerian origin, such as the cervix, endometrium, ovaries and fallopian tubes, is known to have some common genetic or biological characteristics (Vang et al, 2001). The predisposition to VTE might be one common biological characteristic of clear cell histology in the endometrium and ovary.

Venous thromboembolism is one of the major postoperative complications of endometrial cancer. Obesity, diabetes mellitus and high oestrogen state, which often accompany endometrial cancer, all represent risk factors for VTE (Ageno et al, 2008). In addition, smoking, immobility, autoimmune disease, varicosity, giant pelvic tumours, congestive cardiac failure and hyperlipidaemia are known risk factors for VTE after surgery. However, silent VTE before treatment was not associated with obesity, smoking or diabetes mellitus in this study (Table 1). In the univariate and multivariate analyses of risk factors for VTE before the commencement of treatment in 154 patients without VTE before treatment, DD ≥ 1.5 μg ml⁻¹ before treatment, obesity (BMI > 35 kg/m²) and FIGO stage III/IV were all independent and significant risk factors (data not shown). Advanced disease, extraperitoneal spread or FIGO stage III/IV and DD ≥ 1.5 μg ml⁻¹ before treatment were risk factors for VTE both before and after starting treatment, whereas non-endometrioid histology was a risk factor for VTE before treatment and obesity was a risk factor for VTE after starting treatment.

In the guidelines for preventing VTE following general surgery reported at the sixth American College of Chest Physicians Consensus Conference (Greets et al, 2001), patients with gynaecologic malignancies are classified as the highest risk group. These guidelines focused on the prevention of postoperative VTE and recommended the use of elastic stockings and intermittent pneumatic compression during and after surgery, and anticoagulant therapy after surgery in patients with gynaecologic malignancies. However, this study and our recent study revealed that patients may have silent or subclinical VTE even before treatment in the presence of endometrial or ovarian cancer. Given that VTE before treatment may represent the highest risk for VTE after the commencement of treatment unless special management is performed, preoperative assessment of VTE may be important for reducing the incidence of VTE after starting treatment.

In conclusion, the measurement of plasma DD level and subsequent VUI revealed that silent or subclinical VTE occurs before surgery in at least around 10% of patients with endometrial cancer, although it might be presumed that if all patients had VUI, slightly more VTE would be found than reported here. Detection of VTE before the treatment and management of VTE may contribute to preventing postoperative VTE. However, VTE can often occur after the commencement of treatment in endometrial cancer patients without VTE before treatment, particularly among those with risk factors such as DD ≥ 1.5 μg ml⁻¹ before surgery, obesity, advanced stage or invasive surgery. We recommend the assessment and management of VTE before and after starting treatment of endometrial cancer as follows: (1) measurement of DD level should be considered before treatment in all patients. (2) Venous ultrasound imaging should be performed before treatment in patients with DD ≥ 1.5 μg ml⁻¹. (3) If VTE was found before cancer treatment, heparin treatment should be started immediately. (4) For the prevention of VTE after starting treatment, heparin should be used after surgery or during chemotherapy at least for patients with DD ≥ 1.5 μg ml⁻¹ before treatment, obesity or advanced stage in addition to patients with VTE before treatment. Further clarification of the risk factors for VTE before and after commencement of treatment is needed to prevent VTE in endometrial cancer.

ACKNOWLEDGEMENTS

This research was in part supported by the Grant-in-Aid for Scientific Research (no. 20591937) from the Ministry of Education, Science and Culture, Japan.

REFERENCES

Ageno W, Becattini C, Brighton T, Selby R, Ramphuisen PW (2008) Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 117: 93 – 102

Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, Moia M, Parazzini F, Rossi R, Sonaglia F, Valarani B, Bianchini C, Gussoni G (2006) A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 243: 89 – 95

Bounameaux H, Girafi K, De Moerloose P, Schneider P-A, Slosman D, Reber G (1991) Measurement of D-dimer in plasma as diagnostic aid in suspected pulmonary embolism. Lancet 337: 196 – 200

Clarke-Pearson DL, Coleman RE, Synan IS, Hinshaw W, Creasman WT (1983) Venous thromboembolism prophylaxis in gynecologic oncology: a prospective, control trial of low-dose heparin. Am J Obstet Gynecol 145: 606 – 613

Am J Obstet Gynecol 110: 429 – 440

Crandon AJ, Koutts J (1983) Incidence of post-operative deep vein thrombosis in gynaecological oncology. Aust N Z J Obstet Gynaecol 23: 216 – 219

Dubuc-Lissoir J, Ehlen T, Heywood M, Plante M (1999) Prevention and treatment of thromboembolic disease in gynaecological surgery. J Soc Obstet Gynaecol Can 21: 1087 – 1094

Goff BA, De La Cuesta RS, Muntz HG, Fleischhacker D, Ek M, Rice LW, Nikrui N, Tamimi HK, Cain JM, Greer AF, Fuller Jr AF (1996) Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 60: 412 – 417

Committee on Practice Bulletins – Gynecology, American College of Obstetricians and Gynecologists (2002) ACOG practice bulletin No. 84. Prevention of deep vein thrombosis and pulmonary embolism. Obstet Gynecol 110: 429 – 440
Gore M, Miller KE, Soong S, Clarke-Pearson DL, Pizzo SV (1984) Vascular plasminogen activator levels and thromboembolic disease in patients with gynecologic malignancies. *Am J Obstet Gynecol* 149: 830–834

Greets WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson Jr FA, Wheeler HB (2001) Prevention of venous thromboembolism. *Chest* 119: 132S–175S

Harrison KA, Haire WD, Pappas AA, Purnell GL, Palmer S, Holdeman KP, Fink LM, Dalrymple GV (1993) Plasma d-dimer a useful tool for evaluating suspected pulmonary embolus. *J Nucl Med* 34: 896–898

Nicolaides AN, Breddin HK, Fareed J, Goldhaber S, Hull HR, Kolodiki E, Myers K, Samama M, Sasahara A (2001) Prevention of venous thromboembolism. International consensus statement guidelines compiled in accordance with the scientific evidence. *Int Angiol* 20: 1–37

Righini M, Gal GL, Lucia SD, Roy P-M, Meyer G, Aujesky D, Bounameaux H, Perrier A (2006) Clinical usefulness of D-dimer testing in cancer patients with suspected pulmonary embolism. *Thromb Haemost* 95: 715–719

Satoh T, Oki A, Uno K, Sakurai M, Ochi H, Okada S, Minami R, Matsumoto K, Tanaka YO, Tsunoda H, Homma S, Yoshikawa H (2007) High incidence of silent venous thromboembolism before treatment in ovarian cancer. *Br J Cancer* 97: 1053–1057

Suzuki N, Kataoka E, Higashiguchi A, Hirao T, Ezawa S, Nemura H, Tomita A, Susumu N, Aoki D (2005) Intermittent pneumatic compression for prevention of pulmonary thromboembolism after gynecologic surgery. *Thromb J* 3: 3–18

Toyoda M, Satoh T, Takano K, Sato NO, Oki A, Tsunoda H, Yoshikawa H (2003) Successful diagnosis of thromboembolism before surgery in a woman with clear cell adenocarcinoma of the endometrium. *Int J Clin Oncol* 10: 444–446

Turpie AGG, Chin BSP, Lip GYH (2002) Venous thromboembolism: pathophysiology, clinical features, and prevention. *BMJ* 325: 887–890

Unno K, Homma S, Satoh T, Nakanishi K, Abe D, Matsumoto K, Oki A, Tsunoda H, Yamagushi I, Nakagawa T, Yoshikawa H, Aonuma K (2007) Tissue factor expression as a possible determinant of thromboembolism in endometrial carcinoma. *Br J Cancer* 96: 290–295

Vang R, Whitaker BP, Farhood AI, Silva EG, Bo YJ, Deavers MT (2001) Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract. *Int J Gynecol Pathol* 20: 252–259

von Tempelhoff GF, Niemann F, Heilmann L, Hommel G (2000) Association between blood rheology, thrombosis and cancer survival in patients with gynecologic malignancy. *Clin Hemorheol Microcirc* 22: 107–130

Wang X, Fu S, Freedman RS, Kabanagh JJ (2006) Venous thromboembolism syndrome in gynecological cancer. *Int J Gynecol Cancer* 16: 458–471

Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, Kovacs G, Mitchell M, Lewandoski B, Kovacs M (2003) Evaluation of d-dimer in the diagnosis of suspected deep-vein thrombosis. *N Engl J Med* 349: 1227–1235